Third Rock cancer startup Revolution Medicines scores $100M in fresh raise
Having swallowed fellow Third Rock-backed Warp Drive Bio’s oncology pipeline and wooed Sanofi $SNY on as a partner, Redwood City-based biotech Revolution Medicines has raised $100 million in a fresh round of funding.
In 2017, the startup Revolution shed its antifungal ambitions and reinvented itself as an oncology company. And in 2018, the company raised $56 million in a venture round aimed at moving its first experimental therapy into the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.